Eliana Merle Analyst Performance

Biotech Equity Research Analyst at UBS Group

Eliana Merle is a stock analyst at UBS Group focused in the medical sector, covering 36 publicly traded companies. Over the past year, Eliana Merle has issued 58 stock ratings, including strong buy, buy, hold, and sell recommendations. While full access to Eliana Merle's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Eliana Merle's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 110 Last 7 Years
Buy Recommendations: 79.81% 83 Buy Ratings
Companies Covered: 36 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	1.0%	1 ratings
Buy	78.8%	82 ratings
Hold	19.2%	20 ratings
Sell	1.0%	1 ratings

Out of 104 total stock ratings issued by Eliana Merle at UBS Group, the majority (78.8%) have been Buy recommendations, followed by 19.2% Hold, 1.0% Strong Buy, and 1.0% Sell.

Best & Worst Calls

Best Call
0000.0%
APLS
Apr 2025
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
ANAB
Nov 2018
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	100.0% of companies on NASDAQ	36 companies

Eliana Merle, an analyst at UBS Group, currently covers 36 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 34 companies	94.4%
	Finance 1 company	2.8%
	Manufacturing 1 company	2.8%

Eliana Merle of UBS Group specializes in stock coverage within the Medical sector, with additional focus on Finance and Manufacturing companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 27 companies	75.0%
MED - DRUGS 5 companies	13.9%
PHARMACEUTICAL PREPARATIONS 2 companies	5.6%
MED - GENERIC DRG 1 company	2.8%
FIN - INVEST MGMT 1 company	2.8%

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
MRNA Moderna	5/4/2026	Boost Price Target	$47.45	$45.00	Neutral
IONS Ionis Pharmaceuticals	4/30/2026	Boost Price Target	$74.83	$115.00	Overweight
REGN Regeneron Pharmaceuticals	4/30/2026	Lower Price Target	$705.68	$917.00	Overweight
RARE Ultragenyx Pharmaceutical	4/29/2026	Lower Price Target	$24.35	$43.00	Overweight
MRNA Moderna	4/2/2026	Boost Price Target	$48.85	$48.00	Equal Weight
APLS Apellis Pharmaceuticals	4/1/2026	Boost Price Target	$40.40	$41.00	Equal Weight
INSM Insmed	4/1/2026	Boost Price Target	$164.74	$237.00	Overweight
IONS Ionis Pharmaceuticals	3/26/2026	Boost Price Target	$72.70	$106.00	Overweight
QURE uniQure	3/23/2026	Lower Price Target	$15.88	$25.00	Equal Weight
BBIO BridgeBio Pharma	3/10/2026	Reiterated Rating	$74.32		Overweight
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
REGN Regeneron Pharmaceuticals	3/6/2026	Initiated Coverage	$764.93	$923.00	Overweight
TPG TPG	3/2/2026	Lower Price Target	$43.49	$56.00	Overweight
GOSS Gossamer Bio	2/24/2026	Downgrade	$0.42		Underweight
PTCT PTC Therapeutics	2/23/2026	Reiterated Rating	$70.66	$120.00	Overweight
VRTX Vertex Pharmaceuticals	2/17/2026	Boost Price Target	$491.47	$607.00	Overweight
MRNA Moderna	2/16/2026	Reiterated Rating	$42.23	$36.00	Neutral
TPG TPG	2/6/2026	Set Price Target	$53.54	$69.00
APLS Apellis Pharmaceuticals	1/28/2026	Initiated Coverage	$21.81	$24.00	Equal Weight
BBIO BridgeBio Pharma	1/28/2026	Initiated Coverage	$77.87		Overweight
QURE uniQure	1/27/2026	Initiated Coverage	$24.37	$31.00	Equal Weight
TYRA Tyra Biosciences	1/27/2026	Initiated Coverage	$31.40		Overweight
SGMT Sagimet Biosciences	1/27/2026	Initiated Coverage	$6.09	$8.00	Equal Weight
MBX MBX Biosciences	1/27/2026	Initiated Coverage	$36.07	$66.00	Overweight
MDGL Madrigal Pharmaceuticals	1/27/2026	Initiated Coverage	$500.39	$964.00	Overweight
KYMR Kymera Therapeutics	1/27/2026	Boost Price Target	$72.15	$133.00	Overweight
IVA Inventiva	1/27/2026	Initiated Coverage	$6.87	$18.00	Overweight
INSM Insmed	1/27/2026	Initiated Coverage	$162.64	$231.00	Overweight
GOSS Gossamer Bio	1/27/2026	Initiated Coverage	$2.64	$9.00	Overweight
ASND Ascendis Pharma A/S	1/27/2026	Initiated Coverage	$238.80	$342.00	Overweight
APLS Apellis Pharmaceuticals	1/27/2026	Upgrade	$23.07		Hold
ASND Ascendis Pharma A/S	1/27/2026	Initiated Coverage	$222.45	$342.00	Overweight
GOSS Gossamer Bio	1/27/2026	Initiated Coverage	$2.55	$9.00	Overweight
INSM Insmed	1/27/2026	Initiated Coverage	$155.89	$231.00	Overweight
IVA Inventiva	1/27/2026	Initiated Coverage	$6.83	$18.00	Overweight
MBX MBX Biosciences	1/27/2026	Initiated Coverage	$35.83	$66.00	Overweight
MDGL Madrigal Pharmaceuticals	1/27/2026	Initiated Coverage	$496.54	$964.00	Overweight
QURE uniQure	1/27/2026	Upgrade	$23.02		Hold
SGMT Sagimet Biosciences	1/27/2026	Upgrade	$5.86		Hold
MRNA Moderna	1/6/2026	Downgrade	$35.66	$34.00	Neutral
MDGL Madrigal Pharmaceuticals	12/19/2025	Set Price Target	$544.41	$900.00

MDGL Madrigal Pharmaceuticals	12/4/2025	Upgrade	$568.57		Strong-Buy
MRNA Moderna	11/21/2025	Reiterated Rating	$23.47		Buy
MRNA Moderna	11/21/2025	Set Price Target	$23.07	$18.00
MRNA Moderna	10/23/2025	Lower Price Target	$26.85	$40.00	Buy
BBIO BridgeBio Pharma	9/12/2025	Boost Price Target	$52.77	$82.00	Buy
ALT Altimmune	8/13/2025	Lower Price Target	$3.85	$24.00	Buy
RAPT Rapt Therapeutics	8/12/2025	Set Price Target	$9.52	$9.00	Neutral
MDGL Madrigal Pharmaceuticals	8/12/2025	Reiterated Rating	$350.83	$523.00	Buy
ANAB AnaptysBio	8/12/2025	Reiterated Rating	$20.10	$20.00	Neutral
ASND Ascendis Pharma A/S	8/8/2025	Reiterated Rating	$183.33	$307.00	Buy
BMRN BioMarin Pharmaceutical	8/5/2025	Boost Price Target	$60.31	$114.00	Buy
ALNY Alnylam Pharmaceuticals	8/1/2025	Boost Price Target	$398.49	$550.00	Buy
SRPT Sarepta Therapeutics	7/21/2025	Reiterated Rating	$13.56		Neutral
PROK ProKidney	7/15/2025	Boost Price Target	$3.84	$8.00	Buy
CVAC CureVac	6/26/2025	Downgrade	$5.42	$5.50	Neutral
RAPT Rapt Therapeutics	5/22/2025	Lower Price Target	$7.10	$8.00	Neutral
ARVN Arvinas	5/15/2025	Lower Price Target	$5.93	$21.00	Buy
KYMR Kymera Therapeutics	5/13/2025	Lower Price Target	$31.02	$70.00	Buy
MRNA Moderna	5/2/2025	Lower Price Target	$27.61	$70.00	Buy
MDGL Madrigal Pharmaceuticals	5/2/2025	Boost Price Target	$315.48	$458.00	Buy
BBIO BridgeBio Pharma	4/30/2025	Boost Price Target	$38.57	$72.00	Buy
CVAC CureVac	4/30/2025	Lower Price Target	$3.65	$12.00	Buy
APLS Apellis Pharmaceuticals	4/29/2025	Initiated Coverage	$17.96	$44.00	Overweight
BMRN BioMarin Pharmaceutical	2/20/2025	Boost Price Target	$67.92	$113.00	Buy
MRNA Moderna	2/19/2025	Lower Price Target	$36.15	$78.00	Buy
ETNB 89BIO	1/31/2025	Boost Price Target	$9.44	$38.00	Buy
AKRO Akero Therapeutics	1/31/2025	Boost Price Target	$53.43	$109.00	Buy
ZNTL Zentalis Pharmaceuticals	1/28/2025	Lower Price Target	$2.38	$2.20	Neutral

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Top Stock Recommendations by Brokerage

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.